未行减瘤手术的晚期卵巢癌患者的结局:单机构回顾性综述
该单机构回顾性分析纳入2005至2013年接受新辅助化疗后经多学科团队评估不适合间期减瘤手术的晚期卵巢癌患者83例(占接受新辅助化疗467例的18%),中位总生存期为18个月(95%CI 10-20个月);多变量分析中仅接受卡铂联合紫杉醇方案与总生存期独立相关(HR 0.49,95%CI 0.29-0.84)。作者认为,对不适合间期减瘤手术的患者,单纯化疗可提供合理的疾病控制,如有可能应使用卡铂联合紫杉醇。
要点
- 83例(18%)接受新辅助化疗的晚期卵巢癌患者未行间期减瘤手术。
- 未行间期减瘤手术患者的中位总生存期为18个月(95%CI 10-20个月)。
- 多变量分析仅卡铂联合紫杉醇方案与总生存期独立相关(HR 0.49,95%CI 0.29-0.84)。
核心结论
- 对不适合间期减瘤手术的患者,单纯化疗可提供合理的疾病控制,如有可能应使用卡铂联合紫杉醇。
研究设计与样本
- 单机构回顾性分析,纳入2005至2013年英国伦敦UCL医院连续接受新辅助化疗的卵巢癌患者,经多学科团队评估不适合间期减瘤手术者83例(占467例的18%)。
主要发现
- 83例未行间期减瘤手术患者中位年龄70岁(范围33-88岁),43例(51.8%)为IV期。
- 83例中43例(51.8%)接受卡铂联合紫杉醇,37例(44.6%)接受卡铂单药,3例(3.6%)接受其他铂类联合方案。
- 未行手术原因:3-4周期新辅助化疗后反应差61/83(73.5%),合并症12/83(14.5%),患者决定4/83(4.8%);6例(7.2%)因临床状况恶化接受不足3周期新辅助化疗。
- 未行间期减瘤手术患者中位总生存期为18个月(95%CI 10-20个月);83例中44例(53%)接受超过2线化疗。
- 单变量分析中卡铂联合紫杉醇、年龄小于70岁、无合并症为影响总生存期的因素;多变量分析中仅接受卡铂联合紫杉醇与总生存期独立相关(HR 0.49,95%CI 0.29-0.84)。
临床怎么用
- 作者认为,对不适合间期减瘤手术的患者,单纯化疗可提供合理的疾病控制,如有可能应使用卡铂联合紫杉醇。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the outcome of patients with advanced ovarian cancer (OC) who were treated without surgery, having received upfront chemotherapy and no interval debulking surgery (IDS). METHODS: Retrospective analysis of medical and chemotherapy records of consecutive patients with OC between 2005 and 2013 at UCL Hospitals London, UK who received neoadjuvant chemotherapy (NACT) was then found to be unsuitable for IDS following review by the multidisciplinary team. RESULTS: Eighty-three patients (18%) out of 467 receiving NACT did not undergo IDS. Median age was 70years (range 33-88); out of these 83 patients, 43 (51.8%) presented with stage IV disease. Forty-three of these 83 patients received carboplatin and paclitaxel (CP) (51.8%) and 37 received carboplatin alone (C) (44.6%); 3 patients (3.6%) received other platinum-based combinations. Reasons for not proceeding to surgery were: poor response to chemotherapy after 3-4 cycles of NACT (61/83, 73.5%); comorbidities (12/83, 14.5%); patient decision (4/83, 4.8%). Six patients (7.2%) received <3 cycles of NACT due to a worsening clinical condition. The median overall survival (OS) for patients not undergoing IDS was 18months (95% CI 10-20months). Forty-four of 83 patients (53%) received >2 lines of chemotherapy. In a univariate analysis CP, age <70years, and absence of comorbidities were factors influencing OS. In a multivariate analysis only having received CP remained independently associated with OS (HR 0.49, 95% CI 0.29-0.84). CONCLUSIONS: Chemotherapy alone can provide reasonable disease control in patients unsuitable for IDS and CP should be used if possible.
引用
- Marchetti C, Kristeleit R, McCormack M, et al. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol. 2016. PMID: 27825669. doi:10.1016/j.ygyno.2016.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。